A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease - Full Text View

Purpose

The objective of this study was to evaluate the efficacy and safety of treatment with 4000 litre (L) alglucosidase alfa (Lumizyme®) in Pompe participants.

Condition	Intervention	Phase
Pompe Disease	Drug: Alglucosidase alfa	Phase 4


Study Type:	Interventional
Study Design:	Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale

Resource links provided by NLM:

Genetics Home Reference related topics: Pompe disease Schindler disease glycogen storage disease type IX succinic semialdehyde dehydrogenase deficiency

Drug Information available for: Alglucosidase Alfa

Genetic and Rare Diseases Information Center resources: Glycogen Storage Disease Type 2

U.S. FDA Resources

Further study details as provided by Sanofi:

Primary Outcome Measures:

Percentage of Participants Who Were Clinically Stable or Improved at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
Clinical stability was defined as absence of death due to disease progression or new dependency on invasive ventilation and; decline in cardiac status, motor function, and pulmonary function from baseline.

Secondary Outcome Measures:

Survival Rate at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
Percentage of participants who were alive at Week 52, were reported. Survival rate was calculated by Kaplan-Meier estimate.
Invasive Ventilator-Free Survival Rate at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
Percentage of participants, who were invasive ventilator-free at week 52, are reported. Invasive ventilation was defined as mechanical ventilatory support applied with the use of an endotracheal tube or tracheostomy. Invasive ventilator-free survival rate was calculated by Kaplan-Meier estimate.
Change From Baseline on Left Ventricular Mass Z-Score (LVM-Z) at Week 52 [ Time Frame: Baseline, Week 52 ] [ Designated as safety issue: No ]
Z-Scores indicate the number of standard deviations (SD) from the mean in a normal distribution. A negative change from baseline indicates an increase in LVM-Z score. The normal range is -2 to 2 and greater than 2 may indicate left ventricular hypertrophy.
Change From Baseline on Gross Motor Function Measure-88 (GMFM-88) at Week 52 [ Time Frame: Baseline, Week 52 ] [ Designated as safety issue: No ]
GMFM-88 (88-item measure to detect gross motor function) consists of 5 components, each measured on a 4-point Likert scale.The score for each dimension was expressed as a percentage of the maximum score for that dimension.Total score ranges from 0% to 100%, where higher scores indicate better motor functions.
Change From Baseline in Forced Vital Capacity (FVC) at Week 52- At Supine Position [ Time Frame: Baseline, Week 52 ] [ Designated as safety issue: No ]
Percent predicted FVC values are reported. FVC is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in litres. Predicted forced vital capacity is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (observed value)/(predicted value) * 100%.
Change From Baseline in Forced Vital Capacity (FVC) at Week 52- At Sitting Position [ Time Frame: Baseline, Week 52 ] [ Designated as safety issue: No ]
Percent predicted FVC values are reported. FVC is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in litres. Predicted forced vital capacity is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (observed value)/(predicted value) * 100%.


Enrollment:	113
Study Start Date:	March 2012
Study Completion Date:	December 2014
Primary Completion Date:	December 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Alglucosidase alfa Alglucosidase alfa (4000 L scale) intravenous (IV) infusion administered for 52 weeks as per physician's routine practice.	Drug: Alglucosidase alfa 4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks. Other Name: Lumizyme®

Eligibility


Ages Eligible for Study:	1 Year and older (Child, Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

A participant might meet all of the following criteria to be eligible for this study.

The participant and/or their parent/legal guardian was willing and able to provide signed informed consent.
The participant might be at least 1 year of age at the time of informed consent.
The participant had a diagnosis of Pompe disease and might have received treatment with 160 L alglucosidase alfa prior to screening.
The participant, if female and of childbearing potential, might have a negative pregnancy test (urine beta-human chorionic gonadotropin) at baseline. Note: all female participants of childbearing potential and sexually mature males might agree to use a medically accepted method of contraception throughout the study.

Exclusion Criteria:

A participant who met any of the following criteria were to be excluded from this study.

The participant had within the past 3 months received or was currently receiving any investigational product other than 160 L alglucosidase alfa or was currently participating in another clinical treatment study.
The participant, in the opinion of the Investigator, was clinically unstable and would not be expected to survive to completion of the 52-week treatment period.
The participant and/or their parent/legal guardian, in the opinion of the Investigator, was unable to adhere to the requirements of the study.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01526785

Show 51 Study Locations

Sponsors and Collaborators

Genzyme, a Sanofi Company

Investigators


Study Director:	Medical Monitor	Genzyme, a Sanofi Company

More Information


Responsible Party:	Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier:	NCT01526785 History of Changes
Other Study ID Numbers:	AGLU09411 EFC12720
Study First Received:	February 2, 2012
Results First Received:	September 29, 2015
Last Updated:	November 9, 2015
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:


Glycogen Storage Disease Type II Lysosomal Storage Diseases, Nervous System Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases	Metabolism, Inborn Errors Genetic Diseases, Inborn Glycogen Storage Disease Carbohydrate Metabolism, Inborn Errors Lysosomal Storage Diseases Metabolic Diseases

ClinicalTrials.gov processed this record on September 28, 2016